Drug resistant models

- **Comprehensive portfolio of drug resistant models**
- **10+ cancer types**
- **25+ key targets**
- **30+ leading drugs**
- **100+ resistant models**
- **1,000+ validation data**

Wide range of drug resistant models established in multiple strategies

Acquired resistance in tumor-bearing mice

Acquired resistance in cell culture

**Genetic engineering of reported mutations**

PDX based on clinical resistant patients

Our experience and expertise focused on drug resistance

- Collaboration with **100+** clients across the world to develop combinatory or next-generation therapeutic strategies

- **400+** projects delivered with high quality and efficient timeline.

- **20+** experts dedicated to this platform with deep understanding in drug resistance biology

- **10+** years experience in cancer pharmacology

- Multidisciplinary **bioinformatics** and **analytical** capabilities enabling clear and in-depth understanding of mechanisms

- A comprehensive range of models representing **clinically relevant** mechanisms of resistance

Potential strategies for overcoming drug resistance

- Supporting next-generation targeted drug discovery overcoming the acquired resistance, e.g., 4th generation EGFR TKI evaluation in Osimertinib resistant models.

- Exploring potential combination strategies to maximize the therapeutic efficacy and overcome the drug resistance，e.g., Sotorasib（AMG510）combined with SHP2 targeted agents in Sotorasib resistant models.

- Differentiating from the existing drug portfolio. For example，novel antibody-drug conjugates (ADCs) or new modalities in DS-8201 or T-DM-1 resistant models

ONCO WuXi

# Case study: acquired resistant model of KRAS G12C inhibitor

Resistance phenotype

in vivo models

in vitro assays

Resistance mechanism

Overcoming resistance

Small molecule inhibitors

Immune checkpoint inhibitors